子宫动脉栓塞术后静脉羟考酮与吗啡自控镇痛的对照研究
本研究比较子宫肌瘤栓塞术后静脉羟考酮与吗啡患者自控镇痛的安全性及疗效,为回顾性倾向评分匹配病例对照研究。羟考酮组43例、吗啡组60例,两组均未观察到镇痛相关不良事件。羟考酮组重度恶心发生率更低,但差异无统计学意义。
要点
- 子宫肌瘤栓塞术后使用静脉羟考酮PCA未见镇痛相关不良事件。
- 羟考酮PCA组重度恶心发生率低于吗啡组,但无统计学差异。
- 羟考酮组使用355-500μm聚乙烯醇颗粒比例显著高于吗啡组。
核心结论
- 静脉羟考酮PCA在子宫肌瘤栓塞术后使用是安全的。
- 与吗啡PCA相比,羟考酮PCA呈现重度恶心发生率更低的趋势。
研究设计与样本
- 回顾性病例对照研究,采用倾向评分匹配。
- 吗啡对照组来自既往已发表数据集,共69例,匹配后60例。
诊断标准与关键数值
- 羟考酮组重度恶心发生率为37.2%,吗啡组为43.3%,组间差异无统计学意义(P=0.533)。
- 羟考酮组栓塞后综合征发生率为65.1%,吗啡组为48.3%,差异无统计学意义(P=0.091)。
- 多因素logistic回归显示羟考酮与重度恶心风险降低64%相关(OR=0.36,P=0.217)。
- 羟考酮组使用355-500μm聚乙烯醇颗粒的比例为100%,吗啡组为18%,差异有统计学意义(P<0.001)。
临床应用与阅片要点
- 子宫肌瘤栓塞术后可考虑静脉羟考酮PCA作为吗啡的替代镇痛方案。
- 采用较小粒径栓塞颗粒时需警惕栓塞后综合征发生率可能升高。
局限性
- 回顾性设计,对照组来自既往发表数据集。
- 两组栓塞颗粒使用存在显著差异,可能影响结局比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The use of intravenous oxycodone is still limited in the Interventional Radiology setting. This study aimed to assess the safety and efficacy of intravenous oxycodone used in patient-controlled analgesia (PCA) after uterine fibroid embolisation (UFE), compared to morphine.
METHODS: Retrospective case-control study. The study group consisted of patients treated with UFE between March and December 2024, using an oxycodone protocol. The control group consisted of a previously published dataset using morphine protocol. Primary outcomes were safety and the incidence of severe nausea.
RESULTS: There were 57 patients in the oxycodone group compared to 69 in the morphine group. After propensity score matching, this left 43 in the oxycodone group and 60 in the morphine group. Groups were similar in terms of background demographics, however the use of smaller 355-500 micrometre polyvinyl alcohol particles were higher in the oxycodone group (100% vs 18%, p < 0.001).No analgesic-related adverse events were observed in either group. The incidence of severe nausea was lower in the oxycodone group (43.3% vs 37.2%, p = 0.533) despite a higher rate of post-embolisation syndrome (65.1% vs 48.3%, p = 0.091). After multiparametric logistic regression, oxycodone was associated with a 64% reduced odds of severe nausea (OR 0.36, p = 0.217).
CONCLUSIONS: Intravenous oxycodone PCA is safe and showed a trend towards a lower incidence of severe nausea compared with morphine PCA.
ADVANCES IN KNOWLEDGE: There is limited evidence of the use of oxycodone PCA to treat post-embolisation syndrome. This study showed it was safe and resulted in reduced nausea compared to morphine.
引用
- Clements, Markakis, Koukounaras, et al. Intravenous oxycodone versus morphine patient-controlled analgesia (PCA) after uterine artery embolisation: A propensity matched case-control study. Br J Radiol. 2026. PMID: 42928627. doi:10.1093/bjr/tqag262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。